Latest Headlines

Latest Headlines

Duke, NIAID track HIV evolution with eyes on creating a vaccine

A team led by the Duke Human Vaccine Institute and the National Institute of Allergy and Infectious Diseases has tracked the evolution of HIV and the body's corresponding immune response, hoping now to turn the knowledge gained into an experimental vaccine.

Gilead's latest HIV cocktail wins FDA approval with a blockbuster pedigree

Gilead Sciences won FDA approval for another combination treatment for HIV, building around a cornerstone antiviral therapy as it works to expand its dominance in the field.

J&J;, ViiV tout trial showing their long-acting HIV-fighting injectables are comparable to daily pills

Johnson & Johnson's Janssen announced that a combination therapy of two intramuscular injections of HIV medications administered simultaneously monthly or bimonthly demonstrated comparability to a daily three-drug oral therapy during an ongoing Phase II trial.

Two HIV-preventing vaginal ring studies promise protection for women in developing countries

Vaginal rings that release antiretroviral drugs to prevent AIDS hold promise in developing countries to stem the spread of the disease and empower women by allowing them to control their own drug regimens. And research communities are hailing two new trials in Africa for safety and efficacy.

Vaginal ring shields some women from HIV in NIH-backed study

A large study funded by the National Institutes of Health (NIH) found that a drug-delivering vaginal ring could protect some women against HIV. The results come on the heels of more promising data, which show that the ring device can reduce women's risk of developing the infection.

Norway's Bionor tests drug-vaccine combo against HIV

Antiretroviral treatments sometimes fail to work in people with HIV because of the virus' ability to "hide" in cells and then reemerge once therapy stops. Norway's Bionor tested anticancer drug romidepsin and a vaccine, Vacc-4x, in 17 HIV-positive patients in the hopes that the combo would force the virus out of hiding and then kill it.

GSK adds Bristol-Myers pipeline drugs to challenge Gilead in HIV

It wasn't all that long ago that GlaxoSmithKline was considering a spinoff for its HIV drugs division, ViiV Healthcare. Now, though, the company is hanging on tight to that business--and building it up, too.

Bristol-Myers flips its HIV pipeline to GlaxoSmithKline's ViiV in a $3B deal

Bristol-Myers Squibb is getting out of HIV R&D;, selling its pipeline to the GlaxoSmithKline-controlled ViiV Healthcare in a transaction worth as much as $3 billion.

Survey: Rates of HIV in Asia could reflect 'hidden epidemic'

China now counts more than half a million people with HIV/AIDS, and a new survey suggests that caseload reflects what could be a "hidden epidemic" in the Asia-Pacific region. Much of the recent increase is among adolescents.

Scripps scientists ID weakness-attacking antibodies in pursuit of HIV vaccine

A team at The Scripps Research Institute in La Jolla this week said they have identified four antibodies to target weaknesses in HIV, touting an "important advance" in HIV vaccine research that could assist in developing a vaccine.